PRLD רווח למניה בשנים עשר החודשים האחרונים Prelude Therapeutics Inc.

Prelude Therapeutics (PRLD) retains a staff of leading biologists through stock option plans, focusing on lymph node therapy. Drug development relies on AI and synthesis automation, although clinical trials remain the responsibility of physicians. Fundamental TTM net income per share demonstrates the business's building momentum, and -0.78 shows the current value of the metric. Efficient clinic supply chains and strict temperature control of precursors support the company's margins.

Net income per share over 12 months measures the company's total specific earnings across four quarters. Steady growth in this metric confirms the business's financial stability prior to dividend distribution. By analyzing this 12-month net income per share chart, an investor can identify dangerous divergences between stock quotes and actual performance. For Prelude Therapeutics (PRLD), this metric reflects the monetization of developments in targeted oncology. The precision of small-molecule therapy must convert into growth in fundamental profitability.